Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gross Profit (2021 - 2025)

Historic Gross Profit for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $45.8 million.

  • Rhythm Pharmaceuticals' Gross Profit rose 5565.71% to $45.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.9 million, marking a year-over-year increase of 5630.25%. This contributed to the annual value of $116.8 million for FY2024, which is 7138.54% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Gross Profit stood at $45.8 million for Q3 2025, which was up 5565.71% from $43.0 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Gross Profit peaked at $45.8 million during Q3 2025, and registered a low of $31000.0 during Q1 2021.
  • Its 5-year average for Gross Profit is $17.2 million, with a median of $17.0 million in 2023.
  • In the last 5 years, Rhythm Pharmaceuticals' Gross Profit surged by 624160.58% in 2022 and then surged by 2545.77% in 2025.
  • Rhythm Pharmaceuticals' Gross Profit (Quarter) stood at $1.6 million in 2021, then skyrocketed by 390.96% to $7.8 million in 2022, then skyrocketed by 170.56% to $21.0 million in 2023, then skyrocketed by 81.15% to $38.0 million in 2024, then increased by 20.39% to $45.8 million in 2025.
  • Its last three reported values are $45.8 million in Q3 2025, $43.0 million for Q2 2025, and $29.1 million during Q1 2025.